- Home
- NCNA vs ALZN Comparison
NCNA vs ALZN Comparison
Compare NCNA & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCNA | ALZN |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 4.6M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NCNA | ALZN |
|---|---|---|
| Price | $1.29 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 58.0K | ★ 105.9K |
| Earning Date | 06-01-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.84 |
| 52 Week High | $10.00 | $2.68 |
Technical Indicators
Market Signals| Indicator | NCNA | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 60.78 |
| Support Level | $1.21 | $1.04 |
| Resistance Level | $2.27 | $2.25 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 17.68 | 85.94 |
Price Performance
Historical ComparisonAbout NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.